Zhong Shen

Zhong Shen


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in Biomedical Microdevices
Verified
Journal Article
Closed access
PDF file
YMYanan Mao
Yanan Mao
XZXiufeng Zhang
Xiufeng Zhang
YSYanfang Sun
Yanfang Sun
ZSZhong Shen
Zhong Shen
CZChao Zhong
Chao Zhong
Guohua JiangGuohua Jiang
Guohua Jiang

14 October 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XZXiufeng Zhang
Xiufeng Zhang
JQJianming Qiu
Jianming Qiu
HWHoudong Wang
Houdong Wang
ZLZhenfeng Lu
Zhenfeng Lu
SSShuxian Shao
Shuxian Shao
ZSZhong Shen
Zhong Shen
Recent evidence suggested that autologous concentrated growth factor (CGF), a new bioactive compound from autologous blood is used widely as an ingenious biomaterial in tissue regeneration with anti‐inflammatory properties. This study investigated whether CGF could be involved in the treatment of fistula healing in the anal fistula. For this purpose, the porcine anal fistula model was conducted using the rubber band ligation method and collected pig autogenic CGF to treat the fistulas. CGF treatment promoted fistula healing, which was reflected in the downregulation of inflammatory factors, upregulation of growth factors, and promoted epithelial‐mesenchymal transition with increased collagen synthesis. Besides, 16S rRNA gene sequencing analysis of fistula tissues between the control and CGF groups showed that the microbial populations exhibiting significant differences were VadinCA02, Blastomonas, Deinococcus, Devosia, Sphingomonas, Rubrobacteria, and GW_34. CGF of volunteers were collected to process small interfering RNA‐ (siRNA‐) ERK or siRNA‐negative control transfected human skin fibroblasts (HSF). The results showed that CGF also promoted the proliferation and extracellular matrix‐related functions in HSF, as well as activated the MEK/ERK pathway in vitro and in vivo. Finally, knockdown ERK reversed the effects of CGF in promoting wound healing in HSF. Collectively, our results suggest that the CGF as the bioactive compound from autologous blood exhibited great potential for repairing fistulas as well as promoting the proliferation and migration of human skin fibroblasts by triggering MEK/ERK signaling. These findings provided a fresh perspective for understanding the role of CGF in the management of fistulas.

2 May 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YTYuexiao Tang
Yuexiao Tang
TYTao Yao
Tao Yao
XTXin Tian
Xin Tian
XXXintong Xia
Xintong Xia
XHXingxiao Huang
Xingxiao Huang
YWYing Wu
Ying Wu
Platinum-based chemotherapy drugs can lead to the development of anorexia, a detrimental effect on the overall health of cancer patients. However, managing chemotherapy-induced anorexia and subsequent weight loss remains challenging due to limited effective therapeutic strategies. Growth differentiation factor 15 (GDF15) has recently gained significant attention in the context of chemotherapy-induced anorexia. Here, we report that hepatic GDF15 plays a crucial role in regulating body weight in response to chemo drugs cisplatin and doxorubicin. Cisplatin and doxorubicin treatments induce hepatic Gdf15 expression and elevate circulating GDF15 levels, leading to hunger suppression and subsequent weight loss. Mechanistically, selective activation by chemotherapy of hepatic IRE1α-XBP1 pathway of the unfolded protein response (UPR) upregulates Gdf15 expression. Genetic and pharmacological inactivation of IRE1α is sufficient to ameliorate chemotherapy-induced anorexia and body weight loss. These results identify hepatic IRE1α as a molecular driver of GDF15-mediated anorexia and suggest that blocking IRE1α RNase activity offers a therapeutic strategy to alleviate the adverse anorexia effects in chemotherapy.

11 June 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
HWHaibo Wang
Haibo Wang
RHRongchao He
Rongchao He
DLDeng Liu
Deng Liu
JHJun He
Jun He
ZSZhong Shen
Zhong Shen
Background: Colorectal cancer (CRC) is a major cause of global cancer deaths, with increasing incidence among younger populations. Despite advancements in diagnostic and therapeutic strategies, early detection and effective treatment remain major challenges. Exosomes act as critical intercellular messengers, promoting cancer growth, immune escape, and chemotherapy resistance. This study aims to identify exosome-related biomarkers in CRC and elucidate the functional significance of S100A11 in tumor progression and immune regulation.Methods: We integrated multi-cohort transcriptomic data from TCGA and GEO databases and applied a machine learning triad (LASSO-SVM-Random Forest) to identify robust exosomal biomarkers for CRC. Functional enrichment analysis, immune infiltration evaluation, and molecular docking were performed, along with in vitro and in vivo experiments, including qPCR, Western blot, IHC, apoptosis assays, and xenograft models, were performed to validate the oncogenic and immunoregulatory role of S100A11.Results: A five-gene exosome-based diagnostic panel (S100A11, CA4, PDCD4, GSTM2, SORD) was established, demonstrating excellent predictive accuracy (AUC=0.965). S100A11 was identified as a master regulator of CRC proliferation, immune modulation, and chemoresistance. Knockdown of S100A11 significantly suppressed CRC cell proliferation, induced apoptosis, and restrained tumor development in a xenograft model. Moreover, S100A11 was associated with an immunosuppressive tumor microenvironment. Pharmacogenomic analysis revealed its potential as a therapeutic target, with high binding affinity to diallyl trisulfide, suggesting novel treatment avenues.Conclusion: S100A11 mechanistically promotes CRC progression by activating oncogenic signaling and reshaping the immune microenvironment, positioning it as a clinically relevant dual-function biomarker. The integration of bioinformatics, machine learning, and experimental validation underscores the potential of exosome-derived markers for immunotherapy and precision oncology. Future studies should focus on clinical validation and the development of exosome-based immune-targeted therapies for CRC management.

1 April 2018
Verified
Journal Article
Closed access
XZX-F Zhang
X-F Zhang
YZY. Zhang
Y. Zhang
ZSZhong Shen
Zhong Shen
GYG-G Yang
G-G Yang
HWH-D Wang
H-D Wang
JQJ-M Qiu
J-M Qiu

13 January 2026 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
HWHoudong Wang
Houdong Wang
SSShuxian Shao
Shuxian Shao
WSWenjie Shen
Wenjie Shen
ZSZhong Shen
Zhong Shen
RHRongchao He
Rongchao He